

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

3DMed

思路迪

3D Medicines Inc.

思路迪医药股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1244)

**VOLUNTARY ANNOUNCEMENT
INCREASE IN SHAREHOLDING BY DIRECTOR AND SINGLE LARGEST
SHAREHOLDER AND SENIOR MANAGEMENT**

This announcement is made by 3D Medicines Inc. (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company was recently informed by Dr. Gong Zhaolong (“**Dr. Gong**”), the founder, chairman, executive Director and chief executive officer of the Company, and certain members of the senior management of the Company (“**Senior Management Members**”), that Dr. Gong purchased a total of 20,000 ordinary shares from the open market from September 3, 2024 to September 4, 2024, while the Senior Management Members purchased 10,000 and 11,000 ordinary shares from the open market on September 2, 2024 and September 3, 2024 respectively. Dr. Gong and the Senior Management Members intend to use their own financial resources to purchase no more than 1,000,000 ordinary shares of the Company from the open market based on the market conditions for approximately 12 months from the date of this announcement (“**Share Purchase Plan**”). Dr. Gong currently has no intention to increase his shareholding to the extent that will trigger the obligations to make a mandatory offer under the Codes on Takeovers and Mergers and Share Buy-backs.

The Board considers that the Share Purchase Plan indicates unswerving confidence in the Company’s prospects and growth potential, as well as Dr. Gong’s and the Senior Management Members’ long-term commitment to the Company.

Based on the publicly available information to the Company and as far as the Board is aware, the Company has maintained sufficient public float of the Shares as at the date of this announcement.

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board

Hong Kong, September 4, 2024

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Pai, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.